Rare co-existance of disease or pathology Background:
Background
A 15-year old female patient presented with a case of with eosinophilic pneumonia. Development of chronic eosinophilic pneumonia ( Figure 1 ) in childhood is a rare phenomenon. We tried to analyze the immunological mechanism involved in the development of eosinophilic pneumonia. Eosinophilic pneumonia is recognized both as an eosinophil-associated disease as well as bronchial asthma. It is obvious that in eosinophilic pneumonia the site of eosinophilic infiltration is mainly the alveolus and the peripheral airway; the disability of pulmonary function is restrictive, as opposed to that of bronchial asthma, which has a relatively central side bronchus region and obstructive function. However, the antigen of eosinophilic pneumonia is still unknown, unlike bronchial asthma. Eosinophil-and T-lymphocyte-activated parameters such as ECP, CD4HLADR/CD4 (%), CD4CD25/CD4 (%), and IL-5 are the immunological factors usually discussednot only in the context of bronchial asthma [1] but also in eosinophilic pneumonia [2, 3] .
Case Report
Chronic eosinophilic pneumonia during childhood is very rare [4] . In December 1997, a 15-year-old girl with chronic refractory pneumonia was referred to Habikino Hospital for evaluation of respiratory distress, dry cough, high temperature, chest pain, pulmonary infiltration, and peripheral eosinophilia. In our hospital, she was diagnosed as having chronic eosinophilic pneumonia for the first time by eosinophilia both in bronchial alveolar lavage fluid (BALF) and in peripheral blood, and eosinophils mainly infiltrated the alveolus region, as shown by fiberscope biopsy. A report of laboratory investigations done on the patient is summarized in Table 1 .
Clinical symptoms of eosinophilic pneumonia including increased body temperature, chest pain and dry cough were observed when the patient was admitted to the hospital. Laboratory investigations showed an increase in blood sedimentation rate (BSR). Serological testing (Table 1 ) results for sedimentation antibody of hypersensitivity pneumonia were all negative. Forced vital capacity (FVC) was found to be decreased and showed a restrictive pattern (%FVC; 39%) in spirometry.
Radiographic examinations (Figure 1 ) of recurrence showed a peripheral infiltration wandering shadow, which is characteristic of chronic eosinophilic pneumonia on plain chest radiograph and a computed tomography scan of the chest. The culture tests of BALF and sputum showed that they were negative. Trans-bronchial biopsy demonstrated intra-alveolar infiltration of eosinophils and interstitial infiltration of both eosinophils and lymphocytes. These features were consistent with the diagnosis of chronic eosinophilic pneumonia. Changes in %FVC and forced expiratory volume/1 second (FEV1.0%) in the recurrence of the disease are shown in Table 2 and Figure 4 .
Changed data of %FVC and FEV1.0% on recurrence are shown in Table 2 and Figure 4 .
Percent FVC and FEV1.0% [4] was measured using a portable spirometer (Microspiro HI-601, NIHON-KPHDEN COPOLATION, Tokyo Japan). Data of %FVC changed slightly over time.
The percent FVC measurement obtained using non-invasive methods like spirometry was taken as an indicator of her condition. On admission with eosinophilic pneumonia, her %FVC was extremely low (39%), and we thought that non-invasive spirometry testing could be used as a parameter for recurrence. There was an initial remission followed by a decrease in %FVC to values below 100%, indicating the disease recurrence. FEV1 also responded, so the patient might have had a slight tendency to bronchial asthma. Table 3 shows 12 recurrences of eosinophilic pneumonia. , and CD4CD25/CD4 (%) on remission, recurrence, and active phase. During all these phases, the level of each of these factors was higher in BALF than in peripheral blood. This phenomenon indicates that higher levels inflammation existed in BALF than in peripheral blood. Figure 3 . sIL2R, ECP, and IL5. Although the level of IL5 was higher than the other factors, the levels of sIL2R and ECP were not higher in BALF than that in the peripheral blood. These results seem strange and we have no explanation for this phenomenon. To control eosinophilic pneumonia, 5 different dosages of inhaled steroids were tried, chosen to avoid adverse effects due to long-term systemic administration of steroids. The controller (ICS) became a single use of steroid inhalation therapy, but several months later, the recurrence of eosinophilic pneumonia symptoms often appear. However systemic treatment using predonine can easily control the disease, and the laboratory data and clinical symptoms showed improvement. Table 3 . Eosinophilic pneumonia recurred 12 times despite various steroid inhalation therapies. To control the disease condition and to avoid adverse effects associated with systemic administration of steroids, we tried 5 different dosages of steroids through the inhalation route. The controller became single use of steroid inhalation therapy, but after several months, the eosinophilic pneumonia symptoms re-appeared.
BSR -blood sedimentation rate; Pulmicort T -pulmicort turbuhaler; Pulmicort S -pulmicort suspension; Eo -eosinophil % in peripheral blood.
Discussion
General (non-specific) inflammation parameters are listed in Table 1 .
ESR, CRP, and percentage eosinophils were found to be increased in the peripheral blood of the patient. Spirometry showed a forced pattern typical of eosinophilic pneumonia, as shown by an extreme decrease in %FVC. Decreased %FVC may be attributed to an increased accumulation of inflammatory cells, which differs from obstructive dysfunction of bronchial asthma.
Before steroid therapy, eosinophils increased in both BALF (65%) and peripheral blood (33%). An increased expression of HLADR was seen in CD4-positive T-lymphocytes in BALF (62.8%) as compared to that in peripheral blood (6.4%). The expression of CD25 was also found to be increased in CD4-positive T-lymphocytes in BALF (25.5%) compared to peripheral blood (15.5%). The expression of CD25 in CD8-positive T-lymphocytes was almost equal in BALF and peripheral blood. Even in the active phase of bronchial asthma, HLADRCD4/CD4 and CD25CD4/CD4 increased by several percent (1); however, in eosinophilic pneumonia, they increased by at least 10 percent, showing the extremely high levels of inflammation in eosinophilic pneumonia.
In peripheral blood, soluble interleukin 2 receptor concentration (3963 IU/ml) on admission decreased to 1553 IU/ml in remission phase and then increased again to 2504 IU/ml in recurrent phase. In BALF, the concentration of soluble interleukin 2 receptor was below 250 IU/ml during the active phase. Similarly, the concentration of ECP decreased from 206.6 mcg/ml in the active phase to 26.4 mcg/ml in the remission phase and then increased again to 139.1 mcg/ml during the recurrent phase in peripheral blood. The concentration of ECP in BALF was 20.4 mcg/ml. The concentration of interleukin 5 increased to 16.9 pg/ml only in BALF. The concentration of interleukin 5 in peripheral blood was under 7.8 pg/ml.
It is obvious that the T-lymphocyte activation parameters (CD4HLADR/CD4 (%), CD4CD25/CD4 (%) and IL5), also considered as eosinophil-associated activation parameters, increased in BALF more than in peripheral blood. The concentrations of soluble interleukin 2 receptor and ECP in peripheral blood during the active phase were higher than that in BALF (Figure 3) . The low values given by volume unit such as ECP and soluble interleukin 2 receptor could not be evaluated due to dilution of normal saline using BALF. On the other hand, the concentration of soluble interleukin 2 receptor increases during malignant diseases [5] and decreases during eosinophil-related diseases. The concentrations of both soluble interleukin 2 receptor and ECP [6] in peripheral blood are reflective of eosinophilic pneumonia. The real results of ECP, IL-5, and soluble interleukin 2 receptor in peripheral tissue should be higher. Eosinophil-related activation parameters are activated in the peripheral airway in chronic eosinophilic pneumonia. By accidental inhalation, antigens that are smaller than asthmatic antigens reach peripheral airways and may cause chronic eosinophilic pneumonia.
Pulmonary function in eosinophilic pneumonia
In this study, %FVC is recognized as a parameter for eosinophilic pneumonia. In fact, change in %FVC was observed along with clinical symptoms like a rise in temperature, chest pain, and respiratory distress, change in percentage of eosinophil in peripheral blood and altered BSR. Sveinsson et al. [7] previously reported that FEV1 and %FVC are decreased in eosinophilic pneumonia. In this study, it was observed that %FVC had a relationship with other clinical and laboratory parameters but not with FEV1%. As compared to other parameters, %FVC offers various advantages in prediction of chronic eosinophilia. The procedure to determine %FVC is non-invasive, quick, less expensive, and less laborious. This is the first study in which %FVC was used as a parameter for predicting eosinophilic pneumonia and in which the disease recurrences were managed using ICS treatments.
Inhaled steroid in eosinophilic pneumonia
Our results show that activated T-cells and eosinophilic inflammation existed mainly in peripheral airways rather than in peripheral blood. We considered that inhaled steroid is useful [8] for treating peripheral airway inflammation in chronic eosinophilic pneumonia. But other group considered inhaled steroids not effective [8] . Chan et al. [9] reported a patient who underwent treatment with systemic corticosteroids followed by inhaled steroids and who remained in remission for 2 years. We tried 5 kinds of inhaled steroids during the active and the remission phases of eosinophilic pneumonia to avoid the adverse effects associated with systemic administration of steroids, but we could not achieve sufficient efficacy using inhaled steroids. A roentgen photograph ( Figure 1 ) showed a borderless, cloudy, and wandering shadow-like appearance of the peripheral lung area. Pulmonary function of eosinophilic pneumonia showed a restrictive pattern. Single use of ICSs could not control the persistence of remission. Three reasons may have contributed to the lack of response. Firstly, the particle size of the inhaled steroid was large and hence could not reach the inflammation region and peripheral lung area, whereas Qval (Beclomethasone, pMDI) releases super-small aerosol (diameter 1.1 µm). The second reason could be the weak anti-inflammatory effect of inhaled steroids themselves. As seen in the roentgen image, the bronchus might be closed by the accumulation of inflammatory cells. Inhaled steroids with smaller particle size [10] and strong anti-inflammatory effects are needed for the treatment of eosinophilic pneumonia.
